Pinpointing who will and won’t get Alzheimer’s disease is tricky for doctors, but new research suggests it may soon get ...

What exactly is Alzheimer’s disease, and how common is it? A: Alzheimer’s disease is a neurodegenerative disease that causes dementia. It is caused in part by the accumulation of abnormally folded ...

Dr. Nicholas Milano of Medical University of SC says medications such as Lecanemab and donanemab give Alzheimer's patients ...

This outperformance is indicative of investor confidence in the pharmaceutical giant's ambitious transformation strategy as it navigates the post-Humira period.

The FDA expanded the uses of GE HealthCare’s Vizamyl imaging agent for highlighting the presence of beta amyloid proteins in the brain, with new green lights that enable more objective sc | The ...

The FDA’s regular communications based on reports from its drug safety report database don’t always rattle investors’ cages.

US FDA approves expanded label for GE HealthCare’s Vizamyl PET imaging agent for beta amyloid detection: Arlington Heights, Illinois Thursday, June 26, 2025, 13:00 Hrs [IST] GE ...

Insulin resistance detected by routine triglyceride-glucose (TyG) index can flag people with early Alzheimer's who are four ...

The revised label expands the brain-scan agent's use, and means that Vizamyl can now be used to diagnose Alzheimer's and predict the development of dementia due to disease, the company said. The ...

A simple blood test could reveal which early Alzheimer’s patients are most at risk for rapid decline. Researchers found that ...

AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its anti-amyloid antibody ALIA-1758, which is in phase 1 testing. If consummated ...